Use of human tissue to assess the oncogenic activity of melanoma-associated mutations

Nature Genetics

Volumn 37, Issue 7, 2005, Pages 745-749

  Chudnovsky, Yakov ^a,b   Adams, Amy E ^a,b   Robbins, Paul B ^a,b   Lin, Qun ^a,b   Khavari, Paul A ^a,b  

^a VA PALO ALTO HEALTH CARE SYSTEM   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MUTANT PROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN AKT3; PROTEIN KINASE B; PROTEIN P53; RAF PROTEIN; UNCLASSIFIED DRUG; CDK4 PROTEIN, HUMAN; CDK4 PROTEIN, MOUSE; CYCLIN DEPENDENT KINASE; CYCLIN DEPENDENT KINASE 4; DNA BINDING PROTEIN; ONCOPROTEIN; PHOSPHATASE; PTEN PROTEIN, HUMAN; TELOMERASE; TERT PROTEIN, HUMAN; TERT PROTEIN, MOUSE; TUMOR SUPPRESSOR PROTEIN;

ARTICLE; CANCER INHIBITION; CELL GROWTH; CONTROLLED STUDY; GENE AMPLIFICATION; GENE DELETION; GENE MUTATION; GENE TRANSFER; HUMAN; HUMAN CELL; MELANOMA; ONCOGENE; ONCOGENE RAS; PRIORITY JOURNAL; PROTEIN EXPRESSION; SKIN CANCER; ANIMAL; BIOSYNTHESIS; CANCER INVASION; CELL CULTURE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; MELANOCYTE; METABOLISM; MOUSE; MOUSE MUTANT; MUTATION; PATHOLOGY; SKIN; SKIN TUMOR; TRANSPLANTATION;

ANIMALS; CELLS, CULTURED; CYCLIN-DEPENDENT KINASE 4; CYCLIN-DEPENDENT KINASES; DNA-BINDING PROTEINS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, RAS; HUMANS; MELANOCYTES; MELANOMA; MICE; MICE, SCID; MUTATION; NEOPLASM INVASIVENESS; PHOSPHORIC MONOESTER HYDROLASES; PROTO-ONCOGENE PROTEINS; PTEN PHOSPHOHYDROLASE; SKIN; SKIN NEOPLASMS; TELOMERASE; TRANSPLANTS; TUMOR SUPPRESSOR PROTEIN P53; TUMOR SUPPRESSOR PROTEINS;

EID: 22844445932     PISSN: 10614036     EISSN: 15461718     Source Type: Journal    
DOI: 10.1038/ng1586     Document Type: Article

References (30)

1. Gilchrest, B.A., Eller, M.S., Geller, A.C. & Yaar, M. The pathogenesis of melanoma induced by ultraviolet radiation. N. Engl. J. Med. 340, 1341-1348 (1999).
2. Schaffer, J.V., Rigel, D.S., Kopf, A.W. & Bolognia, J.L. Cutaneous melanoma-past, present, and future. J. Am. Acad. Dermatol. 51, S65-S69 (2004).
3. Davies, H. et al. Mutations of the BRAF gene m human cancer. Nature 417, 949-954 (2002).
4. Pollock, P.M. et al. High frequency of BRAF mutations in nevi. Nat. Genet. 33, 19-20 (2003).
5. Rodolfo, M., Daniotti, M. & Vallacchi, V. Genetic progression of metastatic melanoma. Cancer Lett. 214, 133-147 (2004).
6. Tsao, H., Goel, V., Wu, H., Yang, G. & Haluska, F.G. Genetic interaction between NRAS and BRAF mutations and PTEN/MMAC1 inactivation in melanoma. J. Invest. Dermatol. 122, 337-341 (2004).
7. Wu, H., Goel, V. & Haluska, F.G. PTEN signaling pathways in melanoma. Oncogene 22, 3113-3122 (2003).
8. Stahl, J.M. et al. Deregulated Akt3 activity promotes development of malignant melanoma. Cancer Res. 64, 7002-7010 (2004).
9. Kamb, A. et al. Analysis of the p16 gene (CDKN2) as a candidate for the chromosome 9p melanoma susceptibility locus. Nat. Genet. 8, 23-26 (1994).
10. Hussussian, C.J. et al. Germline p16 mutations in familial melanoma. Nat. Genet. 8, 15-21 (1994).
11. Hayward, N.K. Genetics of melanoma predisposition. Oncogene 22, 3053-3062 (2003).
12. Wolfel, T. et al. A p16INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma. Science 269, 1281-1284 (1995).
13. Albino, A.P. et al. Mutation and expression of the p53 gene in human malignant melanoma. Melanoma Res. 4, 35-45 (1994).
14. Weltzman, J.B. & Yaniv, M. Rebuilding the road to cancer. Nature 400, 401-402 (1999).
15. Hamad, N.M. et al. Distinct requirements for Ras oncogenesis in human versus mouse cells. Genes Dev. 16, 2045-2057 (2002).
16. Nishimura, E.K. et al. Dominant role of the niche in melanocyte stem-cell fate determination. Nature 416, 854-860 (2002).
17. Sharpless, N.E., Kannan, K., Xu, J., Bosenberg, M.W. & Chin, L. Both products of the mouse Ink4a/Arf locus suppress melanoma formation in vivo. Oncogene 22, 5055-5059 (2003).
18. Kannan, K. et al. Components of the Rb pathway are critical targets of UV mutagenesis in a murine melanoma model. Proc. Natl. Acad. Sci. USA 100, 1221-1225 (2003).
19. Beer, S. et al. Developmental context determines latency of MYC-induced tumorigenesis. PLoS Biol. 2, e332 (2004).
20. Dajee, M. et al. NF-kappaB blockade and oncogenic Ras trigger invasive human epidermal neoplasia. Nature 421, 639-643 (2003).
21. Lazarov, M. et al. CDK4 coexpression with Ras generates malignant human epidermal tumorigenesis. Nat. Med. 8, 1105-1114 (2002).
22. Clark, E.A., Golub, T.R., Lander, E.S. & Hynes, R.O. Genomic analysis of metastasis reveals an essential role for RhoC. Nature 406, 532-535 (2000).
23. Brookes, S., Rowe, J., Gutierrez Del Arroyo, A., Bond, J. & Peters, G. Contribution of p16(INK4a) to replicative senescence of human fibroblasts. Exp. Cell Res. 298, 549-559 (2004).
24. Randerson-Moor, J.A. et al. A germline deletion of p14(ARF) but not CDKN2A in a melanoma-neural system tumour syndrome family. Hum. Mol. Genet. 10, 55-62 (2001).
25. Stewart, S.A. et al. Telomerase contributes to tumorigenesis by a telomere length-independent mechanism. Proc. Natl. Acad. Sci. USA 99, 12606-12611 (2002).
26. Chang, S. & DePinho, R.A. Telomerase extracurricular activities. Proc. Natl. Acad. Sci. USA 99, 12520-12522 (2002).
27. Kinsella, T.M. & Nolan, G.P. Episomal vectors rapidly and stably produce high-liter recombinant retrovirus. Hum. Gene Ther. 7, 1405-1413 (1996).
28. Deng, H., Choate, K.A., Lin, Q. & Khavari, P.A. High efficiency gene transfer and pharmacologic selection of genetically engineered human keratinocytes. Biotechniques 25, 274-280 (1998).
29. Hsu, M., Andl, T., Li, G., Meinkoth, J.L. & Herlyn, M. Cadherin repertoire determines partner-specific gap junctional communication during melanoma progression. J. Cell Sci. 113, 1535-1542 (2000).
30. Kern, S.E. et al. Oncogenic forms of p53 inhibit p53-regulated gene expression. Science 256, 827-830 (1992).